Phillip Jones, MD
Family Medicine · Tupelo, MSNPI 1659399723
Payments from drug & device makers
Across 324 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$681
- Pfizer$560
- Novo Nordisk$525
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$317
- Lilly USA, LLC$317
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,22197%
- Education$1463%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $1,253 |
| AbbVie(2 entities) | 65 | $681 |
| Pfizer | 37 | $560 |
| Novo Nordisk | 23 | $525 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $317 |
| Lilly USA, LLC | 21 | $317 |
| Boehringer Ingelheim | 9 | $169 |
| Supernus Pharmaceuticals, Inc. | 8 | $153 |
| Abbott | 8 | $140 |
| Johnson & Johnson | 8 | $126 |
| GSK | 6 | $104 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $103 |
| Merck | 6 | $82 |
| Idorsia Pharmaceuticals US Inc | 5 | $79 |
| Biohaven Pharmaceuticals, Inc. | 4 | $78 |
| E.r. Squibb & Sons, L.L.C. | 2 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $72 |
| Currax Pharmaceuticals LLC | 4 | $58 |
| Antares Pharma, Inc. | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 3 | $48 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Amgen | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Shire North American Group Inc | 2 | $25 |
| Genentech USA, Inc. | 2 | $24 |
| CSL Behring | 1 | $18 |
| Ardelyx, Inc. | 1 | $18 |
| Biogen | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Bayer | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Neuronetics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$116
How this compares
$5,368 in reported general payments places this provider in the 85th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 226 | $281,433 |
| FarxigaDapagliflozin Propanediol | 273 | $242,238 |
| TrulicityDulaglutide | 152 | $195,336 |
| JardianceEmpagliflozin | 121 | $135,339 |
| MounjaroTirzepatide | 86 | $98,942 |
| EliquisApixaban | 53 | $48,230 |
| JanuviaSitagliptin Phosphate | 36 | $33,842 |
| XareltoRivaroxaban | 31 | $21,033 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 36 | $16,489 |
| TrintellixVortioxetine Hydrobromide | 16 | $12,955 |
| JentaduetoLinagliptin/Metformin Hcl | 13 | $10,764 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,343 |
| Rosuvastatin Calcium | 678 | $7,268 |
| LinzessLinaclotide | 13 | $6,916 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $6,776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $317 | $294,278238 claims |
| Novo NordiskOzempic | $525 | $281,433226 claims |
| AstraZenecaFarxiga | $1,253 | $242,238273 claims |
| Boehringer IngelheimJardiance, Jentadueto | $169 | $146,103134 claims |
| PfizerEliquis, Paxlovid | $560 | $52,51782 claims |
| MerckJanuvia | $82 | $33,84236 claims |
| Johnson & JohnsonXarelto | $126 | $21,03331 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $104 | $14,92327 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $72 | $12,95516 claims |
| AbbVieLinzess | $681 | $6,91613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Tupelo
- Jeanne BensonTupelo$13K
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.